{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T17:54:33Z","timestamp":1781200473366,"version":"3.54.1"},"reference-count":40,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Standard initial therapy of chronic graft vs. host disease (cGVHD) with glucocorticoids results in suboptimal response. Safety and feasibility of therapy with ofatumumab (1000 mg IV on days 0 and 14) and prednisone (1 mg\/kg\/day) was previously established in our phase I trial (n = 12). We now report the mature results of the phase II expansion of the trial (n = 38). The overall NIH severity of cGVHD was moderate (63%) or severe (37%) with 74% of all patients affected by the overlap subtype of cGVHD and 82% by prior acute cGVHD. The observed 6 month clinician-reported and 2014 NIH-defined overall response rates (ORR = complete + partial response [CR\/PR]) of 62.5% (1-sided lower 90% confidence interval=51.5%) were not superior to pre-specified historic benchmark of 60%. Post-hoc comparison of 6 month NIH response suggested benefit compared to more contemporaneous NIH-based benchmark of 48.6% with frontline sirolimus\/prednisone (CTN 0801 trial). Baseline cGVHD features (organ involvement, severity, initial immune suppression agents) were not significantly associated with 6-month ORR. The median time to initiation of second-line therapy was 5.4 months (range 0.9-15.1 months). Failure-free survival (FFS) was 64.2% (95% CI 46.5-77.4%) at 6 months and 53.1% (95% CI 35.8-67.7%) at 12 months, whereas FFS with CR\/PR at 12 months of 33.5% exceeded a benchmark of 15% in post-hoc analysis, and was associated with greater success in steroid discontinuation by 24 months (odds ratio 8 (95% CI 1.21-52.7). This single-arm phase II trial demonstrated acceptable safety and potential efficacy of the upfront use of ofatumumab in combination with prednisone in cGVHD.\u00a0 This trial was registered at www.clinicaltrials.gov as #NCT01680965.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021005552","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T01:54:40Z","timestamp":1634694880000},"page":"259-269","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9605-6436","authenticated-orcid":false,"given":"Aleksandr","family":"Lazaryan","sequence":"first","affiliation":[{"name":"Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Lee","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9362-0556","authenticated-orcid":false,"given":"Mukta","family":"Arora","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology and Transplantation, University of Minnesota Medical Center, Minneapolis, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7430-2226","authenticated-orcid":false,"given":"Jongphil","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian Christopher","family":"Betts","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology and Transplantation, University of Minnesota Medical Center, Minneapolis, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Khimani","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2621-7924","authenticated-orcid":false,"given":"Taiga","family":"Nishihori","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0194-7338","authenticated-orcid":false,"given":"Nelli","family":"Bejanyan","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9945-4381","authenticated-orcid":false,"given":"Hien","family":"Liu","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7394-5185","authenticated-orcid":false,"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation and Cellular Therapies, Mayo Clinic, Jacksonville, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7789-1257","authenticated-orcid":false,"given":"Michael D.","family":"Jain","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6270-3065","authenticated-orcid":false,"given":"Marco L.","family":"Davila","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia Elena","family":"Perez","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmita","family":"Mishra","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Perez Perez","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karlie","family":"Balke","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Ayala","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation and Cellular Therapies, Mayo Clinic, Jacksonville, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonel","family":"Ochoa","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0423-5870","authenticated-orcid":false,"given":"Omar","family":"Castaneda Puglianini","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawan","family":"Faramand","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Alsina","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7920-4636","authenticated-orcid":false,"given":"Hany","family":"Elmariah","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Nieder","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7322-0392","authenticated-orcid":false,"given":"Hugo","family":"Fernandez","sequence":"additional","affiliation":[{"name":"Malignant Hematology and Cellular Therapy at Memorial Healthcare System, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Anasetti","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Pidala","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,1,10]]},"reference":[{"issue":"3","key":"2022011016242281200_B1","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.bbmt.2015.10.018","article-title":"Late acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation","volume":"22","author":"Arora","year":"2016","journal-title":"Biol Blood Marrow Transplant."},{"issue":"2","key":"2022011016242281200_B2","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.bbmt.2014.10.021","article-title":"Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research","volume":"21","author":"Arai","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"issue":"1","key":"2022011016242281200_B3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2008-10-182592","article-title":"Quality of life after allogeneic hematopoietic cell transplantation","volume":"114","author":"Pidala","year":"2009","journal-title":"Blood."},{"issue":"17","key":"2022011016242281200_B4","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-11-319509","article-title":"Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium","volume":"117","author":"Pidala","year":"2011","journal-title":"Blood."},{"issue":"3","key":"2022011016242281200_B5","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.bbmt.2017.10.042","article-title":"Success of immunosuppressive treatments in patients with chronic graft-versus-host disease","volume":"24","author":"Lee","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"issue":"1","key":"2022011016242281200_B6","doi-asserted-by":"crossref","first-page":"e192974","DOI":"10.1001\/jamaoncol.2019.2974","article-title":"Factors associated with successful discontinuation of immune suppression after allogeneic hematopoietic cell transplantation","volume":"6","author":"Pidala","year":"2020","journal-title":"JAMA Oncol."},{"issue":"4","key":"2022011016242281200_B7","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.bbmt.2019.10.019","article-title":"Disability related to chronic graft-versus-host disease","volume":"26","author":"Hamilton","year":"2020","journal-title":"Biol Blood Marrow Transplant."},{"issue":"15","key":"2022011016242281200_B8","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1182\/blood-2011-03-344390","article-title":"Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria","volume":"118","author":"Arai","year":"2011","journal-title":"Blood."},{"issue":"12","key":"2022011016242281200_B9","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1182\/blood-2012-11-465583","article-title":"Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease","volume":"121","author":"Inamoto","year":"2013","journal-title":"Blood."},{"issue":"11","key":"2022011016242281200_B10","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1182\/blood-2018-04-785899","article-title":"How I treat refractory chronic graft-versus-host disease","volume":"133","author":"Sarantopoulos","year":"2019","journal-title":"Blood."},{"issue":"5","key":"2022011016242281200_B11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1053\/bbmt.2001.v7.pm11400948","article-title":"Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease","volume":"7","author":"Arora","year":"2001","journal-title":"Biol Blood Marrow Transplant."},{"issue":"1","key":"2022011016242281200_B12","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bbmt.2011.05.016","article-title":"Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a Children\u2019s Oncology Group study","volume":"18","author":"Gilman","year":"2012","journal-title":"Biol Blood Marrow Transplant."},{"issue":"21","key":"2022011016242281200_B13","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1182\/blood-2009-02-202937","article-title":"Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease","volume":"113","author":"Martin","year":"2009","journal-title":"Blood."},{"issue":"2","key":"2022011016242281200_B14","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood.V72.2.546.546","article-title":"Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation","volume":"72","author":"Sullivan","year":"1988","journal-title":"Blood."},{"issue":"11","key":"2022011016242281200_B15","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.3324\/haematol.2018.195123","article-title":"A phase II\/III randomized, multicenter trial of prednisone\/sirolimus versus prednisone\/ sirolimus\/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801","volume":"103","author":"Carpenter","year":"2018","journal-title":"Haematologica."},{"issue":"8","key":"2022011016242281200_B16","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2014-03-563544","article-title":"Failure-free survival after initial systemic treatment of chronic graft-versus-host disease","volume":"124","author":"Inamoto","year":"2014","journal-title":"Blood."},{"issue":"2","key":"2022011016242281200_B17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bbmt.2016.09.023","article-title":"The biology of chronic graft-versus-host disease: a task force report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in chronic graft-versus-host disease","volume":"23","author":"Cooke","year":"2017","journal-title":"Biol Blood Marrow Transplant."},{"issue":"2","key":"2022011016242281200_B18","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1158\/1078-0432.CCR-15-1443","article-title":"A randomized phase II crossover study of imatinib or rituximab for cutaneous sclerosis after hematopoietic cell transplantation","volume":"22","author":"Arai","year":"2016","journal-title":"Clin Cancer Res."},{"issue":"2","key":"2022011016242281200_B19","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood-2006-01-0233","article-title":"Rituximab for steroid-refractory chronic graft-versus-host disease","volume":"108","author":"Cutler","year":"2006","journal-title":"Blood."},{"issue":"9","key":"2022011016242281200_B20","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.bbmt.2009.04.003","article-title":"Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis","volume":"15","author":"Kharfan-Dabaja","year":"2009","journal-title":"Biol Blood Marrow Transplant."},{"issue":"5","key":"2022011016242281200_B21","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s12185-011-0855-2","article-title":"Rituximab for prevention and treatment of graft-versus-host disease","volume":"93","author":"Kharfan-Dabaja","year":"2011","journal-title":"Int J Hematol."},{"issue":"8","key":"2022011016242281200_B22","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1182\/blood-2013-04-495895","article-title":"Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial","volume":"122","author":"Cutler","year":"2013","journal-title":"Blood."},{"issue":"1","key":"2022011016242281200_B23","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.bbmt.2014.10.029","article-title":"B cells in chronic graft-versus-host disease","volume":"21","author":"Sarantopoulos","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"issue":"25","key":"2022011016242281200_B24","doi-asserted-by":"crossref","first-page":"6145","DOI":"10.1182\/blood-2011-12-395970","article-title":"Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence","volume":"119","author":"Arai","year":"2012","journal-title":"Blood."},{"issue":"8","key":"2022011016242281200_B25","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/s41409-018-0399-7","article-title":"Safety and efficacy of rituximab-based first line treatment of chronic GVHD","volume":"54","author":"Solomon","year":"2019","journal-title":"Bone Marrow Transplant."},{"issue":"9","key":"2022011016242281200_B26","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.bbmt.2015.04.023","article-title":"Corticosteroid-free primary treatment of chronic extensive graft-versus-host disease incorporating rituximab","volume":"21","author":"Solomon","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"issue":"6","key":"2022011016242281200_B27","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.bbmt.2015.03.014","article-title":"Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results","volume":"21","author":"Pidala","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"issue":"3","key":"2022011016242281200_B28","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"issue":"6","key":"2022011016242281200_B29","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","article-title":"Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report","volume":"21","author":"Lee","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"issue":"6","key":"2022011016242281200_B30","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.bbmt.2013.03.014","article-title":"Hand grip strength and 2-minute walk test in chronic graft-versus-host disease assessment: analysis from the Chronic GVHD Consortium","volume":"19","author":"Pidala","year":"2013","journal-title":"Biol Blood Marrow Transplant."},{"issue":"3","key":"2022011016242281200_B31","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2017-03-775767","article-title":"An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease","volume":"130","author":"Martin","year":"2017","journal-title":"Blood."},{"issue":"3","key":"2022011016242281200_B32","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2307\/2531294","article-title":"Confidence limits for probability of response in multistage phase II clinical trials","volume":"41","author":"Atkinson","year":"1985","journal-title":"Biometrics."},{"issue":"3","key":"2022011016242281200_B33","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ejca.2007.10.026","article-title":"A Greenwood formula for standard error of the age-standardised relative survival ratio","volume":"44","author":"Pokhrel","year":"2008","journal-title":"Eur J Cancer."},{"key":"2022011016242281200_B34","author":"Miklos","year":"2021"},{"key":"2022011016242281200_B35"},{"issue":"6","key":"2022011016242281200_B36","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.jtct.2021.02.035","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in chronic graft-versus-host disease: I. The 2020 Etiology and Prevention Working Group Report","volume":"27","author":"Williams","year":"2021","journal-title":"Transplant Cell Ther."},{"issue":"7","key":"2022011016242281200_B37","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jtct.2021.03.033","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in chronic graft-versus-host disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report","volume":"27","author":"Kitko","year":"2021","journal-title":"Transplant Cell Ther."},{"issue":"8","key":"2022011016242281200_B38","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jtct.2021.03.029","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in chronic graft-versus-host disease: IIb. The 2020 Preemptive Therapy Working Group Report","volume":"27","author":"Pidala","year":"2021","journal-title":"Transplant Cell Ther."},{"key":"2022011016242281200_B39","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jtct.2021.05.004","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in chronic graft-versus-host disease: III. The 2020 Treatment of Chronic GVHD Report","volume":"27","author":"DeFilipp","year":"2021","journal-title":"Transplant Cell Ther."},{"issue":"20","key":"2022011016242281200_B40","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/blood-2017-05-786137","article-title":"Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study","volume":"130","author":"Malard","year":"2017","journal-title":"Blood."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/1\/259\/1858154\/advancesadv2021005552.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/1\/259\/1858154\/advancesadv2021005552.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T16:24:58Z","timestamp":1641831898000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/1\/259\/477315\/A-phase-2-multicenter-trial-of-ofatumumab-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,10]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021005552","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,10]]}}}